---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-22-000008"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2022-02-23T23:59:59+00:00"
generated_at: "2026-06-27T05:36:55.019129+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Maravai Q4 revenue $228M, up 132% YoY; net income $127M; 2022 guidance raised to $920-960M

## Summary
- Q4 revenue $228.4M (+132% YoY); net income $127.1M (+778% YoY).
- FY2021 revenue $799.2M (+181% YoY); net income $469.3M; adjusted EBITDA $582.8M.
- Nucleic Acid Production segment Q4 revenue $212.5M (+173% YoY) driven by CleanCap demand for mRNA vaccines.
- 2022 revenue guidance raised to $920M-$960M, implying 15-20% growth over 2021 record.
- Completed debt repricing saving ~$6.8M annually in interest; acquired MyChem for ultra-pure nucleotides.

## SEC filing metadata
- accession: 0001823239-22-000008
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2022-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323922000008/0001823239-22-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323922000008/mrvi-20220223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-22-000008
- JSON: https://secwatch.observer/filing/0001823239-22-000008.json
- Plain text: https://secwatch.observer/filing/0001823239-22-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.